An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes | Zendy

Kevan C. Herold | Zendy; Brian N. Bundy | Zendy; S. Alice Long | Zendy; Jeffrey A. Bluestone | Zendy; Linda A. DiMeglio | Zendy; Matthew J. Dufort | Zendy; Stephen E. Gitelman | Zendy; Peter A. Gottlieb | Zendy; Jeffrey P. Krischer | Zendy; Peter S. Linsley | Zendy; Jennifer B. Marks | Zendy; Wayne D. Moore | Zendy; Antoinette Moran | Zendy; Henry Rodriguez | Zendy; William E. Russell | Zendy; Desmond Schatz | Zendy; Jay S. Skyler | Zendy; Eva Tsalikian | Zendy; Diane K. Wherrett | Zendy; Anette-Gabriele Ziegler | Zendy; Carla J. Greenbaum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Author(s) -

Kevan C. Herold,

Brian N. Bundy,

S. Alice Long,

Jeffrey A. Bluestone,

Linda A. DiMeglio,

Matthew J. Dufort,

Stephen E. Gitelman,

Peter A. Gottlieb,

Jeffrey P. Krischer,

Peter S. Linsley,

Jennifer B. Marks,

Wayne D. Moore,

Antoinette Moran,

Henry Rodriguez,

William E. Russell,

Desmond Schatz,

Jay S. Skyler,

Eva Tsalikian,

Diane K. Wherrett,

Anette-Gabriele Ziegler,

Carla J. Greenbaum

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1902226

Subject(s) - medicine , diabetes mellitus , placebo , hazard ratio , type 2 diabetes , type 1 diabetes , randomization , confidence interval , insulin , gastroenterology , randomized controlled trial , endocrinology , pathology , alternative medicine

Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research